CORT · CIK 1088856
What Corcept Therapeutics Incorporated told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for CORT. More may follow as additional filings are processed.
In its own words
What could break it.
Supplier concentration
- single specialty-pharmacy distribution channelmedium
Corcept distributes its products through a single (exclusive) specialty pharmacy plus a specialty distributor; it transitioned that channel from Optime to Curant in late 2025, concentrating distribution in one provider.
“From 2017 until 2025, we used an exclusive specialty pharmacy vendor, Optime and a specialty distributor to distribute our Products and provide logistical support to physicians and patients.”
SEC filing →As of 2026
Regulatory & policy
- U.S. drug-pricing reform (IRA, state price controls, importation)low
The IRA's effects are not yet known and states are increasingly enacting drug price controls, access restrictions and importation programs that could pressure pricing/reimbursement for Corcept's products.
“Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access, marketing cost disclosure, transparency measures and other measures designed to encourage importation from other countries and bulk purchasing.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Curant Health Georgia, LLC
“In the fourth quarter of 2025, substantially all of our specialty pharmacy services were transferred from Optime to Curant Health Georgia, LLC (“Curant”).”
Cited →
Its suppliers
University of Chicago
“We are required to pay the University of Chicago customary milestone fees and royalties on revenue from products commercialized under the issued patents or patents that may issue pursuant to the pending applications.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch